Last Name

Lydia Usha

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 16040828000.
    My NIH COMMONS name is LUSHA123.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sorscher S, Usha L, Burgess K, Klapko O, Buckingham L. Letter to the Editor: Significance of Clonal Hematopoiesis of Indeterminate Potential. J Natl Compr Canc Netw. 2018 Sep; 16(9):1032-1033. PMID: 30181414.
      View in: PubMed
    2. Mitchell RL, Kosche C, Burgess K, Wadhwa S, Buckingham L, Ghai R, Rotmensch J, Klapko O, Usha L. Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation. J Natl Compr Canc Netw. 2018 May; 16(5):461-466. PMID: 29752319.
      View in: PubMed
    3. Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497. PMID: 29659587.
      View in: PubMed
    4. Klapko O, Ghoulam E, Jakate S, Eswaran S, Usha L. Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy. Anticancer Res. 2017 08; 37(8):4173-4176. PMID: 28739702.
      View in: PubMed
    5. Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. Breast Cancer Res Treat. 2017 Nov; 166(1):315-319. PMID: 28702897.
      View in: PubMed
    6. Usha L, Dewdney SB, Buckingham LE. Tumor Screening and DNA Testing in the Diagnosis of Lynch Syndrome. JAMA. 2016 Jul 05; 316(1):93-4. PMID: 27380347.
      View in: PubMed
    7. Berger D, Waheed S, Fattout Y, Kazlauskaite R, Usha L. False Increase of Estradiol Levels in a 36-Year-Old Postmenopausal Patient With Estrogen Receptor-Positive Breast Cancer Treated With Fulvestrant. Clin Breast Cancer. 2016 Feb; 16(1):e11-3. PMID: 26321606.
      View in: PubMed
    8. Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34. PMID: 25379019; PMCID: PMC4212247.
    9. Katz DA, Abrams RA, Sclamberg JS, Usha L. Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature. Pract Radiat Oncol. 2015 Mar-Apr; 5(2):e61-5. PMID: 25413407.
      View in: PubMed
    10. Ben Musa R, Usha L, Hibbeln J, Mutlu EA. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol. 2014 May 21; 20(19):5912-7. PMID: 24914353; PMCID: PMC4024802.
    11. Usha L, Rao G, Christopherson Ii K, Xu X. Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model. PLoS One. 2013; 8(9):e67895. PMID: 24069135; PMCID: PMC3771967.
    12. Jimenez AM, Growney A, Behrens G, Corbridge C, Chapman DD, Usha L. Hereditary inflammatory breast cancer associated with BRCA2 mutation: a rare disease presentation in mother and daughter. Clin Adv Hematol Oncol. 2012 Jun; 10(6):402-4. PMID: 22895246.
      View in: PubMed
    13. Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med. 2012 Apr 27; 10:79. PMID: 22541066; PMCID: PMC3403898.
    14. Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61. PMID: 21414654.
      View in: PubMed
    15. Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts. J Hematol Oncol. 2008 Aug 14; 1:12. PMID: 18702822; PMCID: PMC2546432.
    16. Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, Kemper M, Batus M, Coon JS. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr; 46(4):397-405. PMID: 17243161.
      View in: PubMed
    17. Cimbaluk D, Usha L, Siziopikou KP. Biclonal breast carcinoma metastatic to a supraclavicular lymph node. Breast J. 2005 Nov-Dec; 11(6):488. PMID: 16297106.
      View in: PubMed
    Usha's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description